uniQure N.V (UQ1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, uniQure N.V (UQ1) has a cash flow conversion efficiency ratio of -0.072x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-16.40 Million ≈ $-19.17 Million USD) by net assets (€228.75 Million ≈ $267.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
uniQure N.V - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how uniQure N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of uniQure N.V for a breakdown of total debt and financial obligations.
uniQure N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of uniQure N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MRC Global Inc
NYSE:MRC
|
-0.070x |
|
Unilever PLC
LSE:ULVR
|
0.353x |
|
Guizhou Redstar Developing Co Ltd
SHG:600367
|
0.010x |
|
Limin Chemical Co Ltd
SHE:002734
|
0.032x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
Zhejiang Tiantie Industry Co Ltd
SHE:300587
|
0.002x |
|
Yindu Kitchen Equipment Co Ltd
SHG:603277
|
0.076x |
|
Array Technologies Inc
NASDAQ:ARRY
|
0.068x |
Annual Cash Flow Conversion Efficiency for uniQure N.V (2016–2024)
The table below shows the annual cash flow conversion efficiency of uniQure N.V from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of uniQure N.V.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
€-182.73 Million ≈ $-213.63 Million |
27.063x | +3951.28% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
€-145.93 Million ≈ $-170.61 Million |
-0.703x | -130.59% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
€-145.06 Million ≈ $-169.59 Million |
-0.305x | -163.05% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
€287.96 Million ≈ $336.65 Million |
0.483x | +187.44% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
€-134.83 Million ≈ $-157.63 Million |
-0.553x | -80.96% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
€-98.68 Million ≈ $-115.37 Million |
-0.305x | +27.85% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
€-76.04 Million ≈ $-88.90 Million |
-0.423x | +41.14% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
€-64.27 Million ≈ $-75.14 Million |
-0.719x | +36.60% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
€-72.19 Million ≈ $-84.40 Million |
-1.134x | -- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more